This document provides product-specific guidance on the demonstration of the bioequivalence of octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg or 30 mg.

Keywords: Bioequivalence, generics, octreotide

Abbreviations:

  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration

Current version

Document history

Share this page